<DOC>
	<DOCNO>NCT01604265</DOCNO>
	<brief_summary>To investigate ability Sativex relieve central neuropathic pain multiple sclerosis subject .</brief_summary>
	<brief_title>A Study Sativex Treatment Central Neuropathic Pain Due Multiple Sclerosis</brief_title>
	<detailed_description>Multiple sclerosis subject clinical diagnosis central neuropathic pain enter seven ten day baseline period , follow four week double blind , randomise , parallel group comparison Sativex , placebo . The study medication self-titrated symptom resolution maximum tolerate allow dose . Visits occur end week one four ( end study ) early withdrew . A follow-up visit occur 30 - 40 day completion withdrawal .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Willing able give inform consent participation study . Male female subject age 18 year . Diagnosed disease subtype multiple sclerosis , relapses/remission expect influence neuropathic pain . Duration multiple sclerosis great six month . Central neuropathic pain , due multiple sclerosis , least three month duration , nociceptive , peripheral neuropathic psychogenic cause appear unlikely expect remain stable duration study . Pain score severity four least four complete Numerical Rating Scale score baseline week . Regular medication regime neuropathic pain stable previous two week , prior reduction tricyclic antidepressant , applicable . Willing reduce dosage amitriptyline , equivalent tricyclic antidepressant , maximum 75 mg per day , applicable . No cannabinoid use ( cannabis , Marinol Nabilone ) least seven day study entry willing abstain use cannabis study . Female subject child bear potential male subject whose partner child bear potential , willing ensure partner use effective contraception study three month thereafter . Able ( investigator opinion ) willing comply study requirement . Willing name notify Home Office participation study . Willing general practitioner consultant , appropriate , notified participation study . History schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Concomitant severe nonneuropathic pain presence illness diabetes mellitus could cause peripheral neuropathic pain . Known strongly suspect alcohol substance abuse consider risk alcohol substance abuse investigator . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . History epilepsy convulsion . Significant renal hepatic impairment show medical history indicate clinical laboratory result sample take baseline . Elective surgery procedure require general anaesthesia schedule study . Terminal illness . Any significant disease disorder , opinion Investigator , could either put subject risk participation study , influence result study , subject 's ability participate study . Female subject pregnant , lactate plan pregnancy course study . Regular levodopa ( Sinemet , Sinemet Plus , Levodopa , Ldopa , Madopar , Benserazide ) therapy within seven day study entry . Known suspected hypersensitivity cannabinoids excipients study medication . Known suspect adverse reaction cannabinoids . Travel outside UK plan study . Donation blood study . Participated pharmacological clinical research study within 30 day study entry . Previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>